Balversa 4 MG
Ended Awarded Last action
- Contract number
- 36C24526N0428
- Awardee
-
Janssen Biotech Inc. UEI NVYMGFA53MN7
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $20,295
Award facts
- Contract value 100% obligated
- $20,295.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Carrollton, TX 75010, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, through Veterans Integrated Service Network 5, awarded a $20,295.20 firm fixed-price delivery order to Janssen Biotech Inc. (doing business as Centocor Ortho Biotech Inc.) for BALVERSA 4 MG, a specialized oncology medication used in cancer treatment. This delivery order was issued on March 20, 2026, with an ultimate completion date of March 24, 2026, and will be performed in Carrollton, Texas. The award carries no set-aside designation, reflecting Janssen Biotech's status as a large commercial pharmaceutical supplier. Janssen Biotech, a subsidiary of Johnson & Johnson headquartered in Horsham, Pennsylvania, specializes in biologic therapies and oncology medications and serves as a prime contractor to the VA system.
This delivery order is issued under the parent Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB), which provides the Veterans Health Administration with a comprehensive procurement vehicle for specialty pharmaceutical products. Janssen Biotech maintains significant indefinite delivery vehicles with the VA, including a $15 million single-award Blanket Purchase Agreement for BALVERSA and related oncology therapies and a $6.89 billion multiple-award Federal Supply Schedule contract supporting drug procurement across Veterans Integrated Service Networks nationwide. The delivery order structure and pricing reflect the firm fixed-price contracting approach used consistently across the VA's oncology medication procurement, enabling rapid fulfillment of critical medical treatment needs for veterans.
Quick answers
Who was awarded contract 36C24526N0428?
36C24526N0428 was awarded to Janssen Biotech Inc. by Veterans Integrated Service Network 5 (Veterans Health Administration) on March 20, 2026.
How much is contract 36C24526N0428 worth?
The government has obligated $20,295 on 36C24526N0428.
Is contract 36C24526N0428 an order under another contract?
Yes. 36C24526N0428 is a delivery order under 36F79724D0176, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0428 competed?
The extent of competition for 36C24526N0428 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award